Supply Chain

Takeda Pharmaceuticals will collaborate with Numerate, a computational drug design company, on a new drug development initiative, reports GEN.

The Senate Health, Education, Labor and Pensions Committee on Tuesday held the first of three hearings dedicated to the issue of high drug costs, reports CNBC.

U.S. News & World Report — in collaboration with Pharmacy Times — on Tuesday released its 2017 list of the top health products recommended by pharmacists.

Institutional Shareholder Services, a major shareholder advisory firm, is urging Mylan stockholders to vote for the removal of 10 board members, including board Chairman Robert Coury and CEO Heather Bresch, reports STAT.

Halyard Health, a medical products supplier, seeks to divest its surgical and infection prevention business, unnamed sources told Reuters.

Drug prices vary greatly among high-income countries with universal healthcare coverage, according to a study published in Canadian Medical Association Journal.

The U.S. Supreme Court on Monday ruled drugmakers will no longer have to wait six months after regulatory approval to launch new biosimilar drugs, reports Reuters.

Lower doses and shorter treatment periods may not reduce the efficacy of many cancer drugs, says a group of oncologists researching ways to lower cancer treatment costs.

Office supplies are typically a large expense for hospitals. Developing and implementing an aggressive, limited office supply formulary can help control these costs, according to Tom Fox, a managing director at healthcare consulting firm Nova Strategies.

The Food and Drug Administration denied Coherus BioSciences' biosimilar version of Amgen's successful cancer drug Neulasta.